الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - tiotropium bromide monohydrate (unii: l64sxo195n) (tiotropium - unii:0eb439235f) - tiotropium 18 ug - spiriva handihaler (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. spiriva handihaler is indicated to reduce exacerbations in copd patients. spiriva handihaler is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, or any components of this product [see warnings and precautions (5.2)] . in clinical trials and postmarketing experience with spiriva handihaler, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported [see warnings and precautions (5.2)]. risk summary the limited human data with spiriva handihaler use during pregnancy are insufficient to inform a drug-associated risk of adverse pregnancy-related outcomes. based on animal reproduction studies, no structural abnormalities were observed when tiotropium was

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

boehringer ingelheim international gmbh - tiotropium bromide monohydrate - inhalation powder, capsule - 18 microgram - anticholinergics

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

boehringer ingelheim international gmbh - tiotropium - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide

سنغافورة - الإنجليزية - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - tiotropium bromide monohydrate eqv tiotropium - capsule - 18 mcg

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

a-s medication solutions - tiotropium bromide monohydrate (unii: l64sxo195n) (tiotropium - unii:0eb439235f) - spiriva handihaler (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. spiriva handihaler is indicated to reduce exacerbations in copd patients. spiriva handihaler is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, or any components of this product [see warnings and precautions (5.2)] . in clinical trials and postmarketing experience with spiriva handihaler, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported [see warnings and precautions (5.2)]. risk summary the limited human data with spiriva handihaler use during pregnancy are insufficient to inform a drug-associated risk of adverse pregnancy-related outcomes. based on animal reproduction studies, no structural abnormalities were observed when tiotropium was

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

merit pharmaceuticals limited - tiotropium bromide - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

b & s healthcare - tiotropium - inhalation powder, capsule - 18 microgram - anticholinergics

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - tiotropium - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - tiotropium -